1. Aapro MS, Alberts DS, Salmon SE (1983) Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10:161–166
2. Ahre A, Björkholm M, Mellstedt H, Brenning G, Engstedt L, Gahrton G, Gyllenhammar H, Holm G, Johansson B, Jämmark M, Kamström L, Killander A, Lemer R, Lockner D, Lönnqvist B, Nilsson B, Simonsson B, Stalfelt A-M, Strander H, Svedmyr E, Wadman B, Wedelin C (1984) Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 68:1331–1338
3. Ahre A, Björkholm M, Österborg A, Brenning G, Gahrton G, Gyllenhammar H, Holm G, Johansson B, Juliusson G, Jämmark M, Killander A, Lemer R, Lockner D, Nilsson B, Simonsson B, Stalfelt A-M, Strander H, Smedmyr B, Svedmyr E, Uden A-M, Wadman B, Wedelin C, Mellstedt H (1988) High doses of natural interferon (EFN) in the treatment of multiple myeloma — a pilot study from the Myeloma Group of Central Sweden (MGCS) Eur J Haematol 41:123–130
4. Alexanian R, Gutterman J, Levy H (1982) Interferon treatment for multiple myeloma. Clin Haematol 11:211–220
5. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bemasconi P, Mantini M, Donti E, Grignani F, Bemasconi C, Dianzani F, Mandelli F (1988) Interferon alpha-2b as therapy for Ph′-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72:642–647